Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) TD Cowen 4th Annual Oncology Innovation Summit May 30, 2023 12:30 PM ET Company Participants Izzy Lowy - SVP, Solid Organ Oncology Development Andres Sirulnik - SVP, Translational & Clinical Sciences, Hematology Ryan Crowe - VP, IR Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren All right. We'll give it a couple of seconds for everyone to join. Okay. So with that, welcome, everyone, again, to the TD Cowen's 4th Annual Oncology Innovation ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 2023 RBC Capital Markets Global Healthcare Conference May 16, 2023 9:30 AM ET Company Participants Aris Baras – Senior Vice President, Regeneron Genetics Center Christos Kyratsous – Senior Vice President-Research Ryan Crowe – Vice President-Investor Relations Conference Call Participants Brian Abrahams – RBC Capital Markets Brian Abrahams Again for being here I'm Brian Abrahams, one of the senior biotech analysts here at RBC Capital Markets. Our next feature com ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bank of America Global Healthcare Conference Call May 9, 2023 4:40 PM ET Company Participants Ryan Crowe - VP, IR Robert Landry - EVP, Finance & CFO Conference Call Participants Geoff Meacham - Bank of America Merrill Lynch Geoff Meacham Welcome to the afternoon of the first day of the BofA Healthcare Conference. So my name is Geoff Meacham. I'm the senior biopharma analyst. And we're excited here to have Regeneron. Bob Landry, CFO is with us, and Ryan's on Stag ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Ryan Crowe - Investor Relations Leonard Schleifer - Chief Executive Officer George Yancopoulos - Co-Founder, President and Chief Scientific Officer Marion McCourt - Executive Vice President and Head of Commercial Bob Landry - Chief Financial Officer Conference Call Participants Mohit Bansal - Wells Fargo Robyn Karnauskas - Truist Tyler Van Buren - Cowen Terence Flynn - Morgan Stanley Chri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 000-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 13- ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Barclays Global Healthcare Conference March 15, 2023 9:00 AM ET Company Participants Ryan Crowe - Vice President of Investor Relations Robert Landry - Chief Financial Officer Conference Call Participants Carter Gould - Barclays Carter Gould [Technical difficulty] -- Barclays Global Healthcare Conference. My name is Carter Gould, senior biopharma analyst, here at Barclays. I am pleased to welcome Regeneron Pharmaceuticals to the stage to help us kickoff the day. ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Oppenheimer 33rd Annual Healthcare Conference March 13, 2023 9:20 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Neil Stahl - Executive Vice President, Research and Development Jamie Orengo - Vice President, Allergy and Immunity Research Conference Call Participants Hartaj Singh - Oppenheimer Hartaj Singh Great. For joining us, I always have to remember to give that pause. Always thank -- a little thankful to the operators for making ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Cowen 43rd Annual Health Care Conference March 6, 2023 12:50 PM ET Company Participants Marion McCourt - EVP of Commercial Ryan Crowe - Vice President & Head of IR Conference Call Participants Tyler Van Buren - Cowen Tyler Van Buren Good afternoon, everyone. I'm Tyler Van Buren here, Senior Biotech Analyst at TD Cowen. Thank you very much for joining us for TD Cowen's 43rd Annual Healthcare Conference. For our next session, very pleased to have a fireside chat w ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) SVB Securities Global Biopharma Conference February 14, 2023 9:20 AM ET Company Participants Ryan Crowe - VP, IR Izzy Lowy - SVP of Clinical Development for Oncology Andres Sirulnik - SVP, Translational & Clinical Sciences, Hematology Conference Call Participants David Risinger - SVB Securities David Risinger So good morning, everybody, and thank you for joining our session with Regeneron. My name is Dave Risinger. I'm responsible for diversified biopharmaceutic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 000-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 13-34446 ...